Immunotherapy for thoracic malignancies Journal Article

  


Authors: Dozier, J.; Chintala, N.; Adusumilli, P.
Article Title: Immunotherapy for thoracic malignancies
Abstract: Purpose: Historically, thoracic malignancies, such as non-small cell lung cancer and malignant pleural mesothelioma, have been marked by poor prognosis. Current standard of care for these diseases results in limited improvements in survival benefit. This has prompted researchers to explore new and innovative treatment alternatives. Immunotherapy is an emerging therapeutic modality that harnesses the power of the human immune system against cancer cells. Herein, we summarize the concepts and current status of immunotherapy for the treatment of thoracic malignancies. Methods: Using ClinicalTrials.gov, we conducted a literature review using the terms “immunotherapy” and “immune therapy,” and combined them with the conditions “pleural mesothelioma” and “carcinoma, non-small cell lung.” The search results yielded 452 trials, among which 122 trials met our specific criteria. Results: Our search identified immune checkpoint blockade, immunotoxin therapy, anticancer vaccines, and adoptive cell therapy as the most common and relevant immunotherapies that are currently being assessed in clinical trials. Conclusion: We have highlighted the successes, as well as the limitations, of immunotherapy for non-small cell lung cancer and malignant pleural mesothelioma. We have identified early phase clinical trials that assess immunotherapy as first-line, second-line, and maintenance therapy, and compared these drugs as monotherapeutics or in combination with chemotherapy or other types of immunotherapy. © 2017, Indian Association of Cardiovascular-Thoracic Surgeons.
Keywords: immunotherapy; non-small cell lung carcinoma; thoracic malignancies
Journal Title: Indian Journal of Thoracic and Cardiovascular Surgery
Volume: 34
Issue: Suppl. 1
ISSN: 0970-9134
Publisher: Indian Association of Cardiovascular-Thoracic Surgeons  
Date Published: 2018-01-01
Start Page: S54
End Page: S64
Language: English
DOI: 10.1007/s12055-017-0566-2
PROVIDER: scopus
DOI/URL:

https://www.scopus.com/inward/record.uri?eid=2-s2.0-85040720052&doi=10.1007%2fs12055-017-0566-2&partnerID=40&md5=5c42855474b4b4e3f33b1816e5df2c86
Notes: Article -- Export Date: 1 February 2018 -- Source: Scopus
Altmetric
What is Altmetric?
Citation Impact
What is Dimensions Citation Badge?
BMJ Impact Analytics
MSK Authors
  1. Prasad S Adusumilli
    498 Adusumilli
  2. Navin Kumar Chintala
    27 Chintala
  3. Jordan Michael Dozier
    9 Dozier
Related MSK Work